BioXcel Therapeutics, Inc.BTAI

時価総額

$1090.1万

PER

神経科学と免疫腫瘍学のバイオ製薬の新興企業。舌下フィルムIGALMI®（FDA承認・2022年4月）やBXCL701の臨床開発を展開。BioXcel LLCが主要株主（8.78%、2025年3月21日）、2024年9月に15名（約28%）の人員削減を実施。米国中心の事業展開。

	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-19	-33	-	-107	-166	-179	-60
Depreciation	-	-	-	-	0	0	0
Amortization of Debt Issuance Costs and Discounts	-	-	-	-	1	1	0
Change in fair value of derivative liabilities	-	-	-	-	-0	0	20
Stock-based compensation expense	3	3	15	19	17	19	6
Paid-in-Kind Interest	-	-	-	-	1	2	7
Loss on disposal of equipment	-	-	-	-0	-0	-0	-
Operating lease right-of-use assets	-	-	-	-	-	0	0
Accounts receivable	-	-	-	-	0	-0	0
Inventory	-	-	-	-	2	0	-1
Prepaid expenses, other current assets and other assets	1	1	2	-0	4	-3	2
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	-	-	-	-	13	-3	-4
Accrued interest	-	-	-	-	4	2	-1
Operating lease liabilities	-	-	-	-0	-0	-0	-0
Net cash used in operating activities	-14	-27	-66	-82	-135	-155	-72
Purchases of equipment and leasehold improvements	0	1	0	0	0	0	-
Net cash from investing activities	-0	-1	-0	-0	-0	-0	-
Proceeds from issuance of common stock and warrants	-	-	-	-	-	-	40
Debt Issuance Costs	-	-	-	-	3	0	-
Payment of principal of Long-term debt	-	-	-	-	-	-	3
Offering costs for common stock and warrants issuance	-	-	-	-	-	1	0
Payment of employee tax obligations related to vesting restricted stock units	-	-	-	-	-	0	0
Exercise of stock options	-	-	1	1	0	1	-
Net cash provided by financing activities	56	18	247	102	96	27	37
Net decrease in cash and cash equivalents	42	-10	181	20	-39	-129	-35
Issuance of stock purchase warrants	-	-	-	-	-	-	3
Fair Value Adjustment of Warrants	-	-	-	-	-	0	0
Interest paid	0	0	0	0	3	8	8
Conversion of accrued interest to long-term debt	-	-	-	-	-	-1	-